Reported 2 days ago
Piper Sandler has raised its price target for Ocular Therapeutix Inc. (NASDAQ:OCUL) to $31 from $21, maintaining an Overweight rating. This adjustment follows an investor dinner where Ocular's management discussed their diabetic retinopathy trial designs and upcoming data readouts. The firm also increased its sales projections for AXPAXLI from $1.9 billion to $3.2 billion, reflecting improved confidence in their development programs.
Source: YAHOO